Gilead Sciences | GILD - Operating Profit

Stock Price
149.37
Daily Change
3.14 2.15%
Monthly
23.08%
Yearly
52.36%
Q1 Forecast
137.58

Gilead Sciences reported $3.51B in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
AbbVie USD 5.81B 1.23B Dec/2025
Agios Pharmaceuticals USD -116.87M 10.19M Sep/2025
ALKERMES USD 89.08M 3.9M Sep/2025
Alnylam Pharmaceuticals USD -29.96M 13.76M Sep/2025
Amgen USD 3.96B 464M Dec/2025
Biogen USD 659.6M 192.2M Sep/2025
BioMarin Pharmaceutical USD -31.69M 308.58M Sep/2025
Bristol-Myers Squibb USD 3.64B 135M Sep/2025
Eli Lilly USD 8.99B 599.9M Dec/2025
Gilead Sciences USD 3.51B 810M Sep/2025
GlaxoSmithKline GBP 1.44B 1.35B Dec/2025
Glaxosmithkline GBP 3.76B 1.32B Sep/2025
Incyte USD 431.31M 120.49M Sep/2025
J&J USD 5.59B 1.81B Dec/2025
Merck USD 6.24B 318M Dec/2025
Moderna USD -260M 647M Sep/2025
Neurocrine Biosciences USD 239.3M 93.7M Sep/2025
Novartis USD 4.5B 363M Sep/2025
Pfizer USD 4.65B 3.99B Dec/2025
PTC Therapeutics USD 3.49M 38.35M Sep/2025
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Sanofi EUR 1.7B 2.17B Dec/2025
Sarepta Therapeutics USD -62.88M 178.46M Sep/2025
United Therapeutics USD 389.3M 112.4M Sep/2025
Vertex Pharmaceuticals USD 1.24B 84.6M Sep/2025